fda compounding restriction

fda compounding restriction

40% Rise in Prescription Weight Loss Costs

The FDA’s proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulk-compounding list will push rural patients toward higher priced branded prescriptions, increase travel distance to pharmacies, and raise out-of-pocket costs. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult